Form 4: Biote Corp. Director Andrew R. Heyer Reports Stock Option Grant and RSU Acquisition

Director Andrew R. Heyer reports acquisition of stock options and restricted stock units (RSUs) in Biote Corp.

Summary

• On May 13, 2025, Andrew R. Heyer, a director of Biote Corp., reported the acquisition of 104,547 stock options with an exercise price of $3.91 and 20,687 Deferred Settlement RSUs.
• The RSUs are fully vested upon grant but will be settled upon separation from service.
• The stock options vest on the earlier of May 13, 2026, or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, contingent upon continuous service.
• Following these transactions, Heyer directly owns 46,123 Deferred Settlement RSUs and 104,547 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine transactions. The grants are a positive for the individual but don't necessarily indicate a strong positive or negative outlook for the company.

Positives

• The grant of stock options and RSUs to a director aligns their interests with those of the shareholders.
• The vesting schedule for the stock options incentivizes continued service through May 13, 2026, or the day prior to the Issuer's 2026 Annual Meeting of Stockholders.

Industry Context

This filing is a routine disclosure of insider transactions, common in publicly traded companies to ensure transparency and prevent insider trading.

Comparison to Industry Standards

• Stock option grants and RSU awards are common forms of executive compensation in publicly traded companies, particularly in the biotech sector.
• Vesting schedules tied to continued service are standard practice to incentivize long-term commitment.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation plans for their executives and directors.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment as it aligns director interests with company performance.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Director, BTMD, Biote Corp., Andrew R. Heyer